PAVmed stock dips premarket after VA contract drives near-double rally in PAVM shares
PAVmed shares dropped 3.4% to $11.64 in premarket trading Thursday, following a 94.7% surge the previous session after its Lucid Diagnostics unit secured a U.S. Veterans Affairs contract for the EsoGuard test. Lucid shares fell 10.6% premarket. Investors are seeking details on test rollout and volumes. PAVmed recently completed a 1-for-30 reverse stock split to meet Nasdaq requirements.
